Menstrual Cycle as Endogenous Pharmacodiagnostic Probe
1 Thomas et al. 2026 — Systems Neuroendocrinology in ME/CFS and Long COVID
Full Citation:: Thomas N, Huang K, Schneider-Futschik EK, et al. Systems neuroendocrinology in ME/CFS and long COVID: a chronobiological framework for hormone-based research. Frontiers in Neuroendocrinology. 2026;82:101268. (Thomas et al. 2026) DOI:: 10.1016/j.yfrne.2026.101268 PMID:: 42320559 Published:: June 19, 2026 (online ahead of print) Study Design:: Narrative review Key Findings::
- Hormonal dysregulation increasingly reported in ME/CFS and Long COVID
- Sex hormone signalling identified as key area of vulnerability given female predominance
- Peripheral hormone levels in isolation have limited utility; chronobiology-aware dense-sampling essential
- Proposes framework integrating circadian rhythms, menstrual cycles, and multi-omic analyses
- Coordinates hypothalamic-pituitary axes with immune, autonomic, nervous, and metabolic functionsRelevance:: Most directly relevant paper for the endogenous pharmacodiagnostic probe concept. Explicitly calls for menstrual-cycle-aware, time-structured sampling in ME/CFS research — the essential foundation for testing drug response by cycle phase. Certainty Assessment:: 0.60 (review; no primary data; online ahead of print; ME/CFS-specific)
2 Jovanovic et al. 2009 — 5-HT1A Receptor and 5-HTT Binding During Menstrual Cycle
Full Citation:: Jovanovic H, Karlsson P, Cerin A, Halldin C, Nordström A-L. 5-HT(1A) receptor and 5-HTT binding during the menstrual cycle in healthy women examined with [(11)C] WAY100635 and [(11)C] MADAM PET. Psychiatry Research: Neuroimaging. 2009;172(1):31–37. (Jovanovic et al. 2009) DOI:: 10.1016/j.pscychresns.2008.07.002 PMID:: 19118985 Published:: April 30, 2009 Study Design:: Within-subject PET study Sample Size:: n=13 (5-HT1A; [11C]WAY100635), n=8 (5-HTT; [11C]MADAM); healthy women Diagnostic Criteria:: healthy volunteers Key Findings::
- NULL RESULT: 5-HT1A receptor binding potential did NOT significantly differ between follicular and luteal phases in any brain region
- 5-HTT binding similarly unchanged
- No correlation between change in estradiol or progesterone and change in 5-HT1A or 5-HTT binding
- Transvaginal ultrasound used for precise cycle phase characterizationRelevance:: Critical null finding constraining the mechanism of the probe hypothesis for serotonergic drugs. If receptor density/availability (BP_ND) does not change across the cycle, then cycle-phase drug response differences cannot be attributed to receptor number changes. Does NOT falsify the probe hypothesis: functional sensitivity (G-protein coupling, second messenger efficacy, downstream gene expression) can differ without binding changes. The null is specifically about receptor availability, not functional output. Certainty Assessment::
- *Quality:*: Medium-High (PET gold standard, within-subject design)
- *Sample:*: Small (n=8–13)
- *Replication:*: Single study; partial replication design strong but small n
- *Score:*: 0.65 (weight: 0.75; discounted: 0.49)3 Petersen et al. 2021 — Striatal Dopamine D2 Receptor Availability and Peripheral 17β-Estradiol
Full Citation:: Petersen N, Rapkin AJ, Okita K, et al. Striatal dopamine D(2)-type receptor availability and peripheral 17β-estradiol. Molecular Psychiatry. 2021;26(6):2038–2047. (Petersen et al. 2021) DOI:: 10.1038/s41380-020-01000-1 PMID:: 33420479 PMCID:: PMC9196143 Published:: January 8, 2021 Study Design:: Within-subject PET study Sample Size:: n=16 healthy women (ages 23–45) Diagnostic Criteria:: healthy volunteers Key Findings::
- NULL RESULT: D2-type receptor availability (BP_ND) did NOT differ between high-estrogen (periovulatory) and low-estrogen (early follicular) phases
- No significant difference in whole striatum, caudate, putamen, or accumbens subregions
- [18F]fallypride used — higher affinity than [11C]raclopride (Nordström 1998)
- Supersedes Nordström 1998 (n=5)Relevance:: Higher-quality null than the original Nordström 1998 D2 PET study. Together with Jovanovic 2009, constrains the receptor-density-change interpretation of the probe hypothesis. Stable D2 availability across cycle does NOT preclude: (a) functional D2 output differences (cAMP signalling, β-arrestin recruitment), (b) differential drug occupancy at D2 (competition effects), or (c) extrasynaptic D2 changes below PET resolution. The probe concept depends on functional pharmacodynamic differences, not receptor density differences per se. Certainty Assessment::
- *Quality:*: High (Molecular Psychiatry, within-subject, high-affinity tracer)
- *Sample:*: Moderate (n=16)
- *Replication:*: Single study; consistent direction with Nordström 1998 (n=5)
- *Score:*: 0.75 (weight: 0.75; discounted: 0.56)4 Bosch et al. 2025 — Female Sex and Estrogens on Drug Pharmacokinetics
Full Citation:: Bosch EL, Sommer IEC, Touw DJ. The influence of female sex and estrogens on drug pharmacokinetics: what is the evidence? Expert Opinion on Drug Metabolism & Toxicology. 2025;21(6):637–647. (Bosch, Sommer, and Touw 2025) DOI:: 10.1080/17425255.2025.2481891 PMID:: 40109018 Published:: 2025 Study Design:: Narrative review Key Findings::
- Women experience adverse drug reactions approximately twice as often as men
- CYP1A2, CYP2D6, CYP3A4 modulated by estrogen — expression and activity vary across menstrual cycle
- UGT enzymes and P-glycoprotein also estrogen-sensitive
- Intraindividual PK differences observed within women due to fluctuating estrogen
- Calls for personalized dosing based on sex and estrogen levelsRelevance:: Provides the pharmacokinetic foundation for the probe concept. If drug clearance varies by cycle phase (PK effect), differences in efficacy/toxicity across phases could be PK-driven rather than PD-driven (receptor-level). This is an essential control variable: to infer receptor-system involvement from cycle-phase drug response, PK confounds must be measured or excluded. Practical implication: any probe study must measure drug serum levels to distinguish PK from PD contributions. Certainty Assessment::
- *Quality:*: Medium (expert review, clinical focus)
- *Sample:*: N/A (review)
- *Replication:*: Synthesizes multiple studies; consistent with FDA guidance on sex differences in PK
- *Score:*: 0.68 (weight: 0.75; discounted: 0.51)5 Rizor et al. 2024 — Menstrual Cycle Hormones and Brain Architecture
Full Citation:: Rizor EJ, Babenko V, Dundon NM, et al. Menstrual cycle-driven hormone concentrations co-fluctuate with white and gray matter architecture changes across the whole brain. Human Brain Mapping. 2024;45(11):e26785. (Rizor et al. 2024) DOI:: 10.1002/hbm.26785 PMID:: 39031470 PMCID:: PMC11258887 Published:: August 1, 2024 Study Design:: Within-subject neuroimaging study Sample Size:: n=30 naturally cycling women Diagnostic Criteria:: healthy volunteers Key Findings::
- 17β-estradiol and LH directly proportional to WM diffusion anisotropy (μFA) across the whole brain
- FSH directly proportional to cortical thickness (CT)
- Progesterone associated with increased tissue volume, decreased CSF volume
- Effects observed across frontal, occipital, temporal, and parietal lobes — NOT limited to classical HPG-axis receptor-dense regions
- First report of simultaneous brain-wide WM microstructure and CT changes coinciding with menstrual hormone rhythmsRelevance:: Demonstrates that menstrual cycle hormones produce measurable, whole-brain structural changes in humans at the macro level. This provides plausibility for the probe hypothesis: if fluctuating hormone concentrations restructure brain architecture (DTI, CT, volume), they certainly influence the micro-level receptor dynamics and drug target systems that the probe concept depends on. Suggests that the probe’s detectable signal (differential drug response) could be substantial enough to measure behaviourally. Certainty Assessment::
- *Quality:*: High (Human Brain Mapping, multimodal DTI+T1, within-subject design)
- *Sample:*: Moderate (n=30)
- *Replication:*: Single study; first of its kind
- *Score:*: 0.70 (weight: 0.75; discounted: 0.53)6 Sellers et al. 2015 — Rapid Estrogen Regulation of Synaptic Connectivity and Cognition
Full Citation:: Sellers K, Raval P, Srivastava DP. Molecular signature of rapid estrogen regulation of synaptic connectivity and cognition. Frontiers in Neuroendocrinology. 2015;36:72–89. (Sellers, Raval, and Srivastava 2015) DOI:: 10.1016/j.yfrne.2014.08.001 PMID:: 25159586 Published:: January 2015 Study Design:: Narrative review Key Findings::
- ERα and ERβ couple to intracellular signalling cascades (MAPK/ERK, PI3K/Akt, CREB) within minutes
- Estrogen receptors transactivate mGluRs and NMDA receptors — direct physical interaction with NR1 and NR2B subunits
- Estrogen enhances LTP via NMDA receptor potentiation; rapid effects on dendritic spine density
- Non-genomic (rapid signalling) pathways distinct from classical genomic (nuclear) estrogen actionRelevance:: Core mechanistic paper establishing oestrogen as NMDA positive allosteric modulator. Under the probe hypothesis: during the follicular/ovulatory phase when oestrogen is high, a drug acting through NMDA signalling would show enhanced efficacy (oestrogen potentiates the receptor target). During the luteal phase when oestrogen is low, the same drug would show reduced efficacy. A drug whose response pattern matches this follicular>luteal profile can be inferred to act through NMDA-signalling pathways — including drugs whose NMDA involvement was previously unrecognized. Certainty Assessment::
- *Quality:*: High (Front Neuroendocrinol, comprehensive review)
- *Sample:*: N/A (review; primarily animal/cell data)
- *Replication:*: Extensively replicated preclinical finding
- *Score:*: 0.72 (weight: 0.50; discounted: 0.36)7 Shadani et al. 2024 — Sex Differences in Psychedelic Actions
Full Citation:: Shadani S, Conn K, Andrews ZB, Foldi CJ. Potential differences in psychedelic actions based on biological sex. Endocrinology. 2024;165(8):bqae083. (Shadani et al. 2024) DOI:: 10.1210/endocr/bqae083 PMID:: 38980913 PMCID:: PMC11259856 Published:: July 1, 2024 Study Design:: Narrative review Key Findings::
- Estrogen influences serotonin neurotransmission: affects synthesis, release, and receptor subtype sensitivity
- Psychedelics (5-HT2A agonists) may show differential therapeutic efficacy across menstrual cycle phases
- Direct interaction between estrogen and the serotonin system — mechanisms include: (a) increased tryptophan hydroxylase (synthesis), (b) reduced SERT expression (reuptake), (c) modulation of 5-HT1A autoreceptor sensitivity
- Calls for investigating cycle-phase effects in psychedelic clinical trialsRelevance:: Explicitly frames the cycle-phase × drug response interaction for serotonin-acting drugs and provides the template methodology for the probe concept. While the review focuses on psychedelics, the estrogen-serotonin interaction is relevant to all serotonergic drugs: SSRIs, SNRIs, triptans, 5-HT3 antagonists, and atypical antipsychotics. Under the probe hypothesis: serotonergic drugs would show differential efficacy by cycle phase because oestrogen modulates the serotonin system at multiple levels. Certainty Assessment::
- *Quality:*: Medium (Endocrinology, focused review)
- *Sample:*: N/A (review; mixed human + animal data)
- *Replication:*: Consistent with broader estrogen-serotonin literature
- *Score:*: 0.58 (weight: 0.75; discounted: 0.44)8 Lee et al. 2012 — CYP450 Expression During Estrous Cycle in Rats
Full Citation:: Lee S-Y, Oh S-J, Yun K-U, et al. Expression of hepatic and ovarian cytochrome P450 during estrous cycle in rats. Archives of Toxicology. 2012;86(1):75–85. (Lee et al. 2012) DOI:: 10.1007/s00204-011-0730-1 PMID:: 21717108 Published:: January 2012 Study Design:: Animal experimental study Sample Size:: Female rats; diestrus vs proestrus comparison Key Findings::
- NULL RESULT: expression and activity of CYP isoforms (CYP1A1, 1A2, 1B1, 2B1, 2C11, 2C12, 2E1, 3A1, 3A2, 4A), cytochrome b5, and NADPH-CYP reductase were NOT significantly different between diestrus and proestrus
- Serum estradiol markedly elevated in proestrus — but CYP system did not track this increase
- Conclusion: ``CYP-dependent system is not sensitive to changes in the estrous cycle''Relevance:: Constrains the PK arm of the probe hypothesis: if CYP expression and activity are stable across cycle phases (in rats), then cycle-phase differences in drug response are more likely PD-driven (receptor-level pharmacodynamics) than PK-driven (metabolism-level clearance differences). This is methodologically important: it argues that PK confounds may be smaller than feared, simplifying probe interpretation. However, this finding is in partial tension with Bosch 2025 (which reports estrogen effects on CYP in humans) — species and isoform specificity may explain the discrepancy. Certainty Assessment::
- *Quality:*: Medium (Arch Toxicol, thorough CYP panel)
- *Sample:*: Animal study (rat model)
- *Replication:*: Single study; no human CYP-estrous data
- *Score:*: 0.55 (weight: 0.50; discounted: 0.28)9 Locci & Pinna 2017 — Neurosteroid Biosynthesis and GABA-A Receptor Subunit Composition
Full Citation:: Locci A, Pinna G. Neurosteroid biosynthesis down-regulation and changes in GABA(A) receptor subunit composition: a biomarker axis in stress-induced cognitive and emotional impairment. British Journal of Pharmacology. 2017;174(19):3226–3241. (Locci and Pinna 2017) DOI:: 10.1111/bph.13843 PMID:: 28456011 PMCID:: PMC5595768 Published:: October 2017 Study Design:: Narrative review Key Findings::
- Allopregnanolone (progesterone metabolite) enhances extrasynaptic and postsynaptic GABA-A inhibition via positive allosteric modulation
- Allo binds at a distinct site from GABA, benzodiazepines, barbiturates, and picrotoxin
- Stress downregulates neurosteroid biosynthesis and shifts GABA-A receptor subunit composition: δ-subunit reduction, α4γ2 upregulation
- Subunit shift directly alters drug sensitivity: benzodiazepines become less effective (lose γ2-site efficacy), neurosteroids become more potent (compensatory)
- δ-subunit-containing extrasynaptic receptors mediate tonic currents — critical for network-level inhibitionRelevance:: Core mechanistic paper for the progesterone→allopregnanolone→GABA-A axis of the probe hypothesis. During the luteal phase, progesterone is high and its metabolite allopregnanolone potently enhances GABA-A signalling. This has two pharmacodiagnostic implications: (1) A drug whose GABA-A activity is allopregnanolone-potentiated will show enhanced efficacy in the luteal phase (additive/synergistic PAM effect), (2) A drug targeting GABA-A that is outcompeted by allopregnanolone (shared binding site) will show reduced efficacy in the luteal phase. The direction of cycle-phase effect distinguishes which GABA-A interaction mechanism the drug uses. Certainty Assessment::
- *Quality:*: High (Br J Pharmacol, comprehensive review)
- *Sample:*: N/A (review; primarily preclinical)
- *Replication:*: Extensively replicated preclinical and clinical (brexanolone RCTs)
- *Score:*: 0.72 (weight: 0.50; discounted: 0.36)